A study indicated that melanoma patients with high tumor burden and JAK1/2 mutations are insensitive to PD-1/PD-L1 blockade, partly because the JAK1/2 mutation hindered the adaptive upregulation of PD-L1 when exposed to IFN-γ57. This evidence concerns the gene JAK1 and melanoma.